BiRd vs. Rd as Initial Therapy in Multiple Myeloma
Status:
Active, not recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, phase III study to investigate the efficacy of combination
therapy with an induction phase utilizing a combination clarithromycin (Biaxin®),
lenalidomide (Revlimid®), dexamethasone (Decadron®), in multiple myeloma patients who are
newly diagnosed and require treatment when compared to patients who receive lenalidomide and
dexamethasone alone.